LAPANIB 250 Tablet: Lapatinib 250 mg - Targeted Oncology Therapy for HER2+ Cancer

Dual Tyrosine Kinase Inhibition: The Mechanism of Lapatinib

Primary Indication: In Combination with Capecitabine for Advanced HER2+ Cancer

Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer Regimen

The Therapeutic Advantage: Crossing the Cell Barrier to Block HER2 and EGFR
Secure Your Monopoly: LAPANIB 250 PCD Pharma Franchise with Specialized Support

Home/Products /lapatinib-250-mg-tablet

About the Product

Description


LAPANIB 250 Tablet (Lapatinib 250 mg) is a highly specialized, oral, targeted cancer medicine classified as a Dual Tyrosine Kinase Inhibitor (TKI). It is a critical treatment component for patients diagnosed with HER2-positive advanced or metastatic breast cancer.

Mechanism and Impact:Lapatinib works by selectively and reversibly binding to the intracellular domain of two key receptors: Human Epidermal Growth Factor Receptor 2 (HER2) and Epidermal Growth Factor Receptor (EGFR). By competitively blocking the signaling pathways, Lapatinib effectively halts the uncontrolled tumor cell growth. This dual-action mechanism is particularly valuable in treating cancers that have progressed following treatment with other HER2-targeted agents.

Key Therapeutic Uses (Combination Therapy):

  • With Capecitabine: For patients whose cancer has progressed after prior therapy including an anthracycline, a taxane, and trastuzumab.

  • With Letrozole: For postmenopausal women with hormone receptor-positive and HER2-positive metastatic breast cancer.

We offer an exclusive PCD Pharma Franchise opportunity for LAPANIB 250, providing partners with monopoly rights in this specialized, high-demand segment of targeted breast cancer therapeutics.

Common side effects include nausea, dizziness, stomach discomfort, muscle pain, headache, and an increased risk of bleeding or bruising.

Rosutyle Gold 20/150 Tablet is prescribed for individuals at high risk of cardiovascular diseases, including heart attack, stroke, and atherosclerosis, especially those with high cholesterol and hypertension.

Use only under medical supervision. Regular monitoring of cholesterol levels, liver function, and bleeding risk is recommended.

Store at room temperature (15-30°C) in a dry place away from direct sunlight and moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

lapatinib-250-mg-tablet What are the business opportunities for Lapatinib 250mg Tablet in the PCD pharma franchise market?

Lapatinib 250mg Tablet has demand in the oncology and specialty medicine segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on cancer care, hospital supply, and specialty pharmaceutical portfolios.

Why should medical distributors include Lapatinib 250mg Tablet in their product range?

Medical distributors and agencies can benefit from demand for targeted cancer therapy under oncologist supervision. Lapatinib is a targeted anti-cancer medication that inhibits specific growth factor receptors involved in tumor growth Commonly used in the treatment of HER2-positive breast cancer as prescribed by oncology specialists Supports advanced cancer treatment protocols in specialized healthcare settings This strengthens a high-value oncology and specialty-care portfolio.

Does Cafoli LifeCare Pvt Ltd offer PCD pharma franchise opportunities for this tablet?

Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Lapatinib 250mg Tablet with promotional support, monopoly rights, attractive packaging, and competitive pricing for distributors and wholesalers.

What benefits do wholesalers get by partnering for this product?

Wholesalers and medical agencies benefit from oncologist prescriptions, hospital and specialty clinic demand, long-term treatment requirements, reliable supply chain support, and good margins in oncology medicines.

How can I become a distributor or franchise partner for Lapatinib 250mg Tablet?

Interested distributors, stockists, and wholesalers can contact Cafoli LifeCare Pvt Ltd to discuss pricing, monopoly territory rights, and distribution opportunities.